The latest call
FetchingAtyr Pharma, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$6.11-1.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Just reported
From Atyr Pharma, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$0.00
Guided
—
No guide given
Actual
-$7.43
Guided
—
No guide given
Actual
-$18.8M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$18.3M | -$25.7M | +29.07% |
| Profit per share | -$7.43 | -$10.60 | +29.91% |
| Free Cash Flow | -$9.6M | -$20.5M | +53.41% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Atyr Pharma, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Atyr Pharma, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.